F19.26 Other psychoactive substance dependence with psychoactive substance-induced persisting amnestic disorder

Name of the Condition

• Other Psychoactive Substance Dependence with Psychoactive Substance-Induced Persisting Amnestic Disorder
• ICD-10 Code: F19.26

Summary

This condition involves a pattern of dependence on non-classified psychoactive substances (excluding alcohol, opioids, or cannabis) alongside a persisting amnestic disorder caused by the substance use. The amnestic disorder is characterized by memory impairment that persists beyond the acute effects of the substance, affecting recall or learning. Dependence is marked by a strong desire to use the substance, difficulty controlling use, and continued use despite negative consequences, including the cognitive impairment from the amnestic disorder.

Causes

The condition stems from chronic use of psychoactive substances that alter brain function, leading to both dependence and substance-induced amnestic disorder. Psychological factors like stress or trauma, combined with the addictive properties of the substance, contribute to dependence. The amnestic disorder arises from direct neurotoxic effects of the substance on memory-related brain structures, which may persist even after substance use ceases.

Risk Factors

• Genetic predisposition to addiction
• Co-occurring mental health disorders (e.g., anxiety, depression)
• Early exposure to psychoactive substances
• Environmental access to substances or social norms supporting use

Symptoms

• Intense cravings or urges to use the substance
• Inability to reduce or control use despite efforts
• Memory impairment (e.g., difficulty recalling recent events or learning new information)
• Withdrawal symptoms when not using (e.g., irritability, fatigue)
• Neglect of personal, occupational, or social responsibilities

Diagnosis

Diagnosis requires a thorough medical and psychological evaluation, including patient self-reports of substance use patterns and cognitive assessments to confirm amnestic disorder. Standardized questionnaires or clinical interviews may be used to assess dependence criteria, while neurocognitive testing evaluates memory function. Laboratory tests or imaging may rule out other causes of amnesia.

Treatment Options

Treatment typically involves a combination of substance use disorder interventions (e.g., counseling, behavioral therapy) and management of the amnestic disorder (e.g., cognitive rehabilitation). Medications may address withdrawal symptoms or co-occurring conditions, while support groups aid in maintaining abstinence. Long-term monitoring is essential to address both dependence and cognitive impairment.

Prognosis and Follow-Up

Prognosis depends on the severity of dependence and the extent of cognitive damage. With sustained abstinence and therapy, some cognitive function may improve, but persisting amnesia may remain. Regular follow-up with healthcare providers and neuropsychological evaluations helps track progress and adjust treatment as needed.

Complications

• Worsening cognitive impairment or permanent memory loss
• Increased risk of accidents or injuries due to memory deficits
• Relapse of substance use, exacerbating amnestic symptoms
• Social or occupational dysfunction from combined dependence and cognitive issues

Lifestyle & Prevention

• Avoiding use of non-classified psychoactive substances
• Engaging in stress-reduction techniques (e.g., exercise, mindfulness)
• Seeking early intervention for substance use concerns
• Maintaining a healthy lifestyle to support cognitive health

When to Seek Professional Help

Seek help if experiencing uncontrollable substance use, memory problems, or withdrawal symptoms. Immediate care is needed for severe cognitive impairment or signs of overdose. Healthcare providers can assess dependence and amnestic disorder and recommend appropriate treatment.

Tips for Medical Coders

Document the presence of both other psychoactive substance dependence and the substance-induced persisting amnestic disorder to support the F19.26 code. Include details on substance type, duration of dependence, and evidence of amnestic symptoms (e.g., cognitive testing results) to ensure accurate coding and clinical correlation.